Literature DB >> 12657886

Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation.

Shuichi Igarashi1, Hokuto Morita, Kyla M Bennett, Yuji Tanaka, Simone Engelender, Matthew F Peters, Jillian K Cooper, Jonathan D Wood, Akira Sawa, Christopher A Ross.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the abnormal expansion of a polyglutamine tract in the huntingtin protein. We have developed PC12 cell lines in which the expression of an N-terminal truncation of huntingtin (N63) with either wild type (23Q) or expanded polyglutamine (148Q) can be induced by the removal of doxycycline. Differentiated PC12 cells induced to express N63-148Q showed cellular toxicity reaching up to 50% at 6 days post-induction. Histone acetyltransferase (HAT) activity and global histone acetylation was significantly decreased in cells expressing truncated huntingtin with mutant but not normal huntingtin. These data suggest that altered chromatin modification via reduction in coactivator activity may cause neuronal transcriptional dysregulation and contribute to cellular toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12657886     DOI: 10.1097/00001756-200303240-00007

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  23 in total

1.  RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death.

Authors:  Núria Martín-Flores; Joan Romaní-Aumedes; Laura Rué; Mercè Canal; Phil Sanders; Marco Straccia; Nicholas D Allen; Jordi Alberch; Josep M Canals; Esther Pérez-Navarro; Cristina Malagelada
Journal:  Mol Neurobiol       Date:  2015-04-16       Impact factor: 5.590

2.  Transcriptome profiling of neuronal model cell PC12 from rat pheochromocytoma.

Authors:  Ramasamy Saminathan; Arjunan Pachiappan; Luo Feng; Edward G Rowan; Ponnampalam Gopalakrishnakone
Journal:  Cell Mol Neurobiol       Date:  2009-02-05       Impact factor: 5.046

Review 3.  Epigenetic mechanisms of neurodegeneration in Huntington's disease.

Authors:  Junghee Lee; Yu Jin Hwang; Ki Yoon Kim; Neil W Kowall; Hoon Ryu
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 4.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 5.  Drug targeting of dysregulated transcription in Huntington's disease.

Authors:  Aleksey G Kazantsev; Steven M Hersch
Journal:  Prog Neurobiol       Date:  2007-02-23       Impact factor: 11.685

6.  Cysteine proteases bleomycin hydrolase and cathepsin Z mediate N-terminal proteolysis and toxicity of mutant huntingtin.

Authors:  Tamara Ratovitski; Ekaterine Chighladze; Elaine Waldron; Ricky R Hirschhorn; Christopher A Ross
Journal:  J Biol Chem       Date:  2011-02-10       Impact factor: 5.157

Review 7.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

8.  Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice.

Authors:  P Matthew Joyner; Ronni M Matheke; Lindsey M Smith; Robert H Cichewicz
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

9.  The Rtt109 histone acetyltransferase facilitates error-free replication to prevent CAG/CTG repeat contractions.

Authors:  Jiahui H Yang; Catherine H Freudenreich
Journal:  DNA Repair (Amst)       Date:  2010-01-18

10.  Misfolding of proteins with a polyglutamine expansion is facilitated by proteasomal chaperones.

Authors:  Erwann Rousseau; Rieko Kojima; Guylaine Hoffner; Philippe Djian; Anne Bertolotti
Journal:  J Biol Chem       Date:  2008-11-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.